Form 4 for TNDM TANDEM DIABETES CARE INC
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0001438133-26-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-19 | 2026-02-17 | TNDM | Hansen Shannon Marie | EVP, CLO | M - OptEx | $0.00 | +3,065 | 22.0K | +16% | $0 |
| DM | 2026-02-19 | 2026-02-17 | TNDM | Hansen Shannon Marie | EVP, CLO | F - Tax | $18.95 | -1,263 | 21.8K | -5% | -$23.9K |
| DM | 2026-02-19 | 2026-02-17 | TNDM | Hansen Shannon Marie | EVP, CLO | M - OptEx | $0.00 | -3,065 | 1,437 | -68% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | M | A | 1,097 | $0.00 | 23,728 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-17 | F | D | 452 | $18.95 | 23,276 | D | — | — | |
| 3 | Common | Common Stock | 2026-02-17 | F | D | 592 | $18.95 | 22,631 | D | — | — | |
| 4 | Common | Common Stock | 2026-02-17 | M | A | 1,437 | $0.00 | 23,223 | D | — | — | |
| 5 | Common | Common Stock | 2026-02-17 | F | D | 219 | $18.95 | 21,786 | D | — | — | |
| 6 | Common | Common Stock | 2026-02-17 | M | A | 531 | $0.00 | 22,005 | D | — | — | |
| 7 | Derivative | Restricted Stock Unit | 2026-02-17 | M | D | 531 | $0.00 | 0 | D | — · — to — | 531 Common Stock | (F3) Awarded on February 15, 2022 pursuant to the Tandem Diabetes Care Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). (F4) Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. (F5) RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 2/15/2023, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. |
| 8 | Derivative | Restricted Stock Unit | 2026-02-17 | M | D | 1,097 | $0.00 | 5,484 | D | — · — to — | 1,097 Common Stock | (F9) Awarded on May 23, 2024 pursuant to the 2023 Plan. (F7) Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. (F10) RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. |
| 9 | Derivative | Restricted Stock Unit | 2026-02-17 | M | D | 1,437 | $0.00 | 1,437 | D | — · — to — | 1,437 Common Stock | (F6) Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). (F7) Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. (F8) RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. |